Quarterly report pursuant to Section 13 or 15(d)


3 Months Ended
Jan. 11, 2022
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Sep. 30, 2019
Dec. 10, 2015
Renumeration amount   $ 3,000        
Consideration amount $ 657,640 502,989        
First payment owed $ 145,000 5,046        
Attorney's fees   $ 235,886        
Interest rate   10.00%        
Accrual of loss on contingency   $ (322,000)        
Compensation for services, description   As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month        
Common stock, par value   $ 0.001 $ 0.001 $ 0.001    
Charles River Laboratories, Inc. [Member]            
Remaining commitment   $ 28,936 $ 28,936      
BICX Holding Company LLC [Member]            
Common stock issued upon convertible debt   2,227,575        
Convertible Promissory Note         $ 4,160,000  
Conversion agreement description   Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment        
Issuance price   $ 2.00        
Amount due to investor   $ 1,138,157        
Board Member [Member]            
Stock options grant     4,000      
Term of options   3 years        
Receive common stock equivalent   $ 5,000        
Consulting services valued   12,428        
Alpine Creek [Member]            
Royalty due   91 $ 91 $ 91    
Total consideration amount   1,531,926        
Payables to Alpine Creek           $ 1,215,000
Paid to Alpine Creek   $ 1,620,000        
Payable per treatment sold           $ 100
Profit holding percentage           50.00%